GBI Expands Drug Product Services with Automated Fill-Finish Capabilities

• GBI Biomanufacturing has expanded its Drug Product (DP) services to include automated sterile fill-finish capabilities.

• The new service supports diverse client needs with options for automated and manual fill-finish at its Florida site.

GBI Biomanufacturing (GBI), a contract development and manufacturing organisation (CDMO), has expanded its Drug Product (DP) services by adding automated sterile fill-finish capabilities at its facility in Florida, USA. This development enhances GBI’s ability to provide end-to-end manufacturing solutions for both Drug Substance (DS) and DP at a single location.

The expanded capabilities offer clients flexibility through a dual approach. Manual aseptic vial filling caters to small, early-stage batches requiring special handling, while automated aseptic liquid filling, which employs ready-to-use components, supports higher-throughput production. This approach reduces human intervention, mitigates contamination risks, and enhances batch consistency, suitable for clinical and commercial-scale projects.

“Adding automated aseptic fill-finish capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies,” said Karl Pinto, CEO of GBI. “Our facility is equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory-compliant drug products.”

The new three-format automated filler can handle vials, syringes, and cartridges. It supports various drug classes, including biologics, vaccines, bioconjugates, and complex large molecules, reinforcing GBI’s position as a versatile CDMO partner.

This addition aligns with GBI’s mission to simplify supply chains for its clients by offering a Single-Source Solution. By integrating DS and DP manufacturing under one roof, the company aims to achieve faster project timelines, improved scalability, and seamless regulatory compliance.